Abstract
Introduction:Trueperella bernardiae is a gram-negative coccobacilli that was initially categorized as coryneform bacteria, and thus frequently, it was not further investigated as a pathogenic organism. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) has revolutionized the identification of bacteria, including T. bernardiae. Now case reports for T. bernardiae infections are starting to be reported, but it remains a rare pathogen for infections. Case Presentation: Here we are reporting a rare case of T. bernardiae bacteremia, presenting with sepsis and imaging finding showing pelvic septic arthritis, micro-abscesses, and osteomyelitis. It would have likely started as urinary tract infection, followed by osteomyelitis and bacteremia. The patient was managed with intravenous vancomycin. The follow-up clinic visit showed clinical improvement. This article also provides a brief literature review of T. bernardiae infections. Conclusion:T. bernardiae infections are rare but have clinical significance. This case adds another case to the literature regarding T. bernardiae infections and especially highlights the point that they can present with a more serious presentation like sepsis. MALDI-TOF helps in the identification of these rare pathogens.
Introduction
Trueperella bernardiae infections are rare. A handful of case reports mention T. bernardiae as the primary pathogen. Our case mentions its presentation as sepsis. Commonly reported cases include less acute presentation, including bone and joint infections, brain abscess, breast abscess, bacteremia, and urinary tract infection (UTI). None of these cases were presented as sepsis. Literature is limited when it comes to its treatment. We managed our case based on the literature review of the prior case reports. Most strains are susceptible to beta-lactams and vancomycin. It is associated with an excellent prognosis if treated with appropriate antibiotics. This article also provides a brief literature review of current case reports available for T. bernardiae infections.
Case Report
A 76-year-old man with a medical history significant for prostate cancer status post-prostatectomy in 2018. He had chronic urinary retention with incontinence postoperatively and had chronic foley catheter with intermittent self-catheterization since 2018. Other medical conditions included sleep apnea and recurrent UTIs. He presented to the emergency department with progressive bilateral lower extremity weakness for 3 weeks and lethargy with chills. He reported pain in both lower extremity and pelvis. He specifically had pain during ambulation, especially while changing position. Due to symptoms, he was now unable to ambulate by himself. He denied any urinary or stool incontinence, had no new urinary symptoms, and no numbness in his legs. At baseline, he was an independent male, lived at home in Missouri with his wife, and had no recent trauma or travel. In the emergency department, he was found to be febrile at 39.5°C, tachycardic up to 156 bpm, and blood pressure documented as 80 systolic over 50 diastolic. He was on room air and had a respiratory rate of 12 bpm. On examination he was confused with Glasgow coma scale of 12. He met the sepsis criteria based on quick Sequential Organ Failure Assessment (qSOFA) scoring [21]. On neurological examination, he had a power of 4/5 on left hip flexion and left knee extension on manual muscle test. The rest of the neurological examination was unremarkable. There was pain on palpation of the inner thigh and groin area; perineal sensations were intact, and rectal tone was intact. Laboratory workup on presentation showed white blood count (WBC) of 6.57 × 109/L (3.5–10.5 × 109/L), with 92.6% neutrophils. General chemistry, including electrolytes, creatinine, and liver tests, was normal. Lactic acid was 1.1 mmol/L (0.5–2.2 mmol/L). He had procalcitonin 0.95 ng/mL (0–0.05 ng/mL). Erythrocyte sedimentation rate (ESR) was 112 mm/h (0–20 mm/h) and C-reactive protein (CRP) was 22 (<0.3 mg/dL). Urinalysis showed leukocytes small; nitrites were negative, and bacteria reported as trace, white blood count >30 hpf (0–3 hpf). He was started on intravenous piperacillin/tazobactam 4.5 g every 8 h and intravenous vancomycin 1 g every 12 h, with an initial working diagnosis of sepsis secondary to possible UTI. Two sets of blood cultures were taken from two different peripheral sites. After 48 h of incubation, both samples showed gram-positive rods in blood. Urine culture showed multiple organisms with a concern of contaminant sample. Magnetic resonance imaging (MRI) cervical, thoracic, and lumbar spine without contrast showed multilevel degenerative spine disease and no evidence of cord compression. Magnetic resonance imaging pelvis showed bilateral pelvic septic arthritis associated with adjacent micro-abscesses and bilateral pubic bone osteomyelitis, which explained his lower extremity and pelvic pain (Fig. 1). Later blood cultures were speciated as T. bernardiae with help of matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF). We were not able to obtain sensitivities for T. bernardiae. After blood cultures were reported, piperacillin/tazobactam was discontinued, and intravenous vancomycin was continued. Clinically his confusion improved, and he was neurologically back to baseline. He completed a 6-week course of intravenous vancomycin. He was seen in outpatient infectious disease clinic visit and was noted to have clinical improvement, and his erythrocyte sedimentation rate and CRP also showed significant improvement.
Contrast enhanced T1-weighted image showing sinus track between pubic tubercle and prostatic bed with surrounding osteomyelitis in pelvic bones (blue arrow).
Contrast enhanced T1-weighted image showing sinus track between pubic tubercle and prostatic bed with surrounding osteomyelitis in pelvic bones (blue arrow).
Discussion
T. bernardiae is a facultative, non-spore-forming, non-motile, anaerobic, gram-positive coryneform coccobacilli. It is catalase and oxidase negative. It has variable hemolytic activity. It was initially named coryneform group 2, later labeled Arcanobacterium bernardiae in 1997, and now classified into the genus Trueperella in 2011 [1, 2]. It is a commensal of human skin flora and oropharynx. However, the literature has also reported the isolation of T. bernardiae in porcine stool [3]. One case report also mentions T. bernardiae infection after significant pig exposure [4]. Interestingly, it has not been considered pathogenic until recently, primarily because of initially being classified as coryneform bacteria, which led to its identification as non-pathogenic commensal. Additionally, because lack of detection or incorrect detection of T. bernardiae in usual culture media made its diagnosis difficult. With the advent of MALDI-TOF mass spectrometry, its identification has been made easier and more efficient [5]. Currently, T. bernardiae infections have been reported in the literature as causing UTIs [6, 7], prosthetic joint infections [8‒10], bacteremia [11‒14], breast abscess [15], brain abscess [16], skin and soft tissue infections/post-surgical infections [11, 14, 17, 18], bone infections excluding prosthetic joint infections [4, 19, 20], and septic thrombophlebitis [13]. Limited case reports are available. Table illustrating a literature review of T. bernardiae infections till date is attached to this case report (Table 1). Infections are more common in immunocompromised populations, especially with a previous history of gastrointestinal and genitourinary malignancy or diabetes mellites. However, infections in immunocompetent hosts have also been documented. There has been no age, gender, or race predilection found in the literature review. Polymicrobial infection with other bacteria is common. Listed coinfection with Staphylococcus aureus, Actinotignum sanguinis, Bacteroides fragilis, Enterococcus avium, Peptoniphilus lacrimalis, Morganella morganii, Peptostreptococcus, Fusobacterium gonidiaformans, and Escherichia coli has been reported [11, 15]. T. bernardiae infection outcomes are favorable and are associated with a cure in all the cases reported in the literature. Of note, this case presented with sepsis, bacteremia, and pelvic joint infection. We hypothesized that due to indwelling foley catheter he might have acquired a UTI and that let him have prostatitis and subsequent pelvis osteomyelitis and septic arthritis. His acute presentation was in the setting of bacteremia which was secondary to his osteomyelitis and pelvis septic arthritis. After the literature review, by searching Arcanobacterium bernardiae and T. bernardiae on PubMed, only six case reports have been found for bone and joint infections, and none of them were associated with sepsis or bacteremia, which makes it the first reported case of T. bernardiae bone and joint infection associated with bacteremia and sepsis. Given the paucity of available literature and case reports, the treatment choice has not been precise. Agents used for treatment have included quinolones, penicillin, cephalosporins, carbapenems, and clindamycin. We did not have susceptibilities for this case, but in view of susceptibility data in literature, vancomycin was chosen for this patient. In the future, with the advent of MALDI-TOF, more data are expected to be documented. The E-test method is the most frequently used method to determine minimum inhibitory concentration [5]. No clinical breakpoints have been determined for T. bernardiae; European Committee on Antimicrobial Susceptibility Testing (EUCAST) and pharmacokinetic and pharmacodynamic (non-species related) clinical breakpoints have been utilized. As per current susceptibility data, resistance has not been much of a concern for T. bernardiae. Resistance to metronidazole, aminoglycosides, and penicillin G, however, has been reported. To conclude, T. bernardiae infections are rare but are now known to have clinical significance. Infections are more commonly seen in immunocompromised hosts with a history of malignancy. Urinary tract remains a common site of primary infection. This case adds another case to the literature regarding T. bernardiae infections and especially highlights the point that they can present with a more serious presentation like sepsis. MALDI-TOF helps in the identification of these rare pathogens. Treatment is associated with a good prognosis. The CARE Checklist has been completed by the authors for this case report, attached as online supplementary material (for all online suppl. material, see https://doi.org/10.1159/000539826).
Summary of case reports mentioning T. bernardiae infections
Reference . | Age/sex . | Presentation . | Organisms identified . | Treatment . | Outcome . | Immuno-compromised . | Sensitivity/resistance patterns . |
---|---|---|---|---|---|---|---|
Lepargneur et al. [6], (1998) | UTI | Arcanobacterium bernardiae | Netilmicin and cefixime followed by oral amoxicillin | Cured | Yes (urothelial carcinoma) | Susceptible to amoxicillin, cephalothin, aminoglycosides, pristinamycin, and cotrimoxazole but resistant to pefloxacin | |
Elsayed et al. [7], 2016 | UTI/pyocystitis | T. bernardiae | Ceftriaxone followed by cefuroxime | Cured | Yes (ESRD and cardiac transplant) | Not available | |
Intravesical gentamicin irrigation | |||||||
Gilarranz et al. [8], (2016) | 73/F | Prosthetic knee infection | T. bernardiae | Oral ciprofloxacin 500 mg bid for 2 weeks | Cured | No | Susceptible to penicillin G, ampicillin, amoxicillin/clavulanate, piperacillin/tazobactam, cefotaxime, imipenem, ciprofloxacin and linezolid. Vancomycin, teicoplanin, erythromycin, and clindamycin were not interpreted |
Tang and Desai [9], (2021) | 71/M | Prosthetic hip infection- | T. bernardiae | 6 weeks of intravenous ceftriaxone followed by cefadroxil | Cured | No | Susceptible to β-lactams, clindamycin and vancomycin, with resistance to ciprofloxacin, aminoglycosides and metronidazole |
Loïez et al. [10], (2009) | Prosthetic Joint infection- | Arcanobacterium bernardiae | Rifampicin plus ofloxacin for 12 weeks | Cured | No | Susceptible to amoxicillin, amoxicillin/clavulanic, cephalothin, cefotaxime, imipenem, erythromycin, clindamycin, rifampicin, teicoplanin, vancomycin, linezolid and levofloxacin and resistant to penicillin G, amikacin and trimethoprim/sulfamethoxazole | |
Casale et al. [11], (2022) | 78/F | Bacteremia and postop infection | T. bernardiae | Piperacillin-tazobactam + metronidazole, then clindamycin (14 days) | Cured | History of breast carcinoma | Susceptible to penicillin, amoxicillin-clavulanic acid, piperacillin/tazobactam, ertapenem, imipenem, meropenem, and non-interpretable due to insufficient evidence (IE) for clindamycin and vancomycin |
History of surgery for squamous infiltrating carcinoma 2 months ago with no additional therapy | |||||||
Roh et al. [12], (2019) | 83/F | Bacteremia | T. bernardiae | Doxycycline (6 days), then meropenem + teicoplanin | Cured | - | Resistant to penicillin G and erythromycin and was susceptible to gentamicin and vancomycin |
Lawrence et al. [13], (2018) | 45/M | Bacteremia and septic thrombophlebitis | T. bernardiae | Susceptible to penicillin, co-amoxiclav, cefuroxime, cotrimoxazole, erythromycin, linezolid, ciprofloxacin, doxycycline, imipenem, amikacin | |||
Schneider et al. [14], (2015) | 45/M | Bacteremia and diabetic foot ulcer | T. bernardiae | IV piperacillin/tazobactam, ciprofloxacin and gentamicin, then amoxicillin for 14 days | Cured | Susceptible to penicillin, piperacillin/tazobactam, linezolid, moxifloxacin, and rifampin | |
Calatrava et al. [15], (2019) | 39/F | Breast abscess | T. bernardiae | Cloxacillin, then amoxicillin-clavulanic acid for 10 days | Cured | Susceptible to ciprofloxacin, gentamicin, imipenem, linezolid, penicillin, rifampicin, tetracycline, vancomycin, and resistant to trimethoprim-sulfamethoxazole, clindamycin, and erythromycin | |
Pan et al. [16], (2019) | 5/M | Brain abscess | T. bernardiae | Triple therapy of vancomycin, cefepime, and metronidazole for 6 weeks, then oral amoxicillin for 6 months | Cured | ||
Cobo et al. [17], (2017) | 69/F | Postop infection | T. bernardiae | Amoxicillin/clavulanate | Cured | History of rectal cancer and chemo in the past | Susceptible to penicillin G, linezolid, amoxicillin/clavulanate, and resistant to ciprofloxacin |
Rattes et al. [18], (2016) | 24/F | Postop infection | T. bernardiae | Piperacillin/tazobactam and vancomycin, then amoxicillin/clavulanate | Cured | Resistant to erythromycin and clindamycin and susceptible to levofloxacin, linezolid, vancomycin, and penicillin | |
Gowe et al. [4], (2018) | 57/M | Bone infection-septic arthritis | T. bernardiae | Doxycycline | Cured | Susceptible to penicillin, ceftriaxone, meropenem, vancomycin, and doxycycline | |
Adderson et al. [19], (1998) | 19/F | Bone infection-osteitis | T. bernardiae | Clindamycin for 6 weeks | Cured | 4-year history of steroids and cyclophosphamide for glomerulonephritis dt SLE | Susceptible to vancomycin, penicillin, clindamycin, and resistant to metronidazole |
Bemer et al. [20], (2009) | 63/M | Bone infection-olecranon bursitis | Arcanobacterium bernardiae | Clindamycin and fusidic acid for 3 weeks | Cured | Susceptible to aminoglycosides, erythromycin, clindamycin, pristinamycin, rifampin, cotrimoxazole, and vancomycin |
Reference . | Age/sex . | Presentation . | Organisms identified . | Treatment . | Outcome . | Immuno-compromised . | Sensitivity/resistance patterns . |
---|---|---|---|---|---|---|---|
Lepargneur et al. [6], (1998) | UTI | Arcanobacterium bernardiae | Netilmicin and cefixime followed by oral amoxicillin | Cured | Yes (urothelial carcinoma) | Susceptible to amoxicillin, cephalothin, aminoglycosides, pristinamycin, and cotrimoxazole but resistant to pefloxacin | |
Elsayed et al. [7], 2016 | UTI/pyocystitis | T. bernardiae | Ceftriaxone followed by cefuroxime | Cured | Yes (ESRD and cardiac transplant) | Not available | |
Intravesical gentamicin irrigation | |||||||
Gilarranz et al. [8], (2016) | 73/F | Prosthetic knee infection | T. bernardiae | Oral ciprofloxacin 500 mg bid for 2 weeks | Cured | No | Susceptible to penicillin G, ampicillin, amoxicillin/clavulanate, piperacillin/tazobactam, cefotaxime, imipenem, ciprofloxacin and linezolid. Vancomycin, teicoplanin, erythromycin, and clindamycin were not interpreted |
Tang and Desai [9], (2021) | 71/M | Prosthetic hip infection- | T. bernardiae | 6 weeks of intravenous ceftriaxone followed by cefadroxil | Cured | No | Susceptible to β-lactams, clindamycin and vancomycin, with resistance to ciprofloxacin, aminoglycosides and metronidazole |
Loïez et al. [10], (2009) | Prosthetic Joint infection- | Arcanobacterium bernardiae | Rifampicin plus ofloxacin for 12 weeks | Cured | No | Susceptible to amoxicillin, amoxicillin/clavulanic, cephalothin, cefotaxime, imipenem, erythromycin, clindamycin, rifampicin, teicoplanin, vancomycin, linezolid and levofloxacin and resistant to penicillin G, amikacin and trimethoprim/sulfamethoxazole | |
Casale et al. [11], (2022) | 78/F | Bacteremia and postop infection | T. bernardiae | Piperacillin-tazobactam + metronidazole, then clindamycin (14 days) | Cured | History of breast carcinoma | Susceptible to penicillin, amoxicillin-clavulanic acid, piperacillin/tazobactam, ertapenem, imipenem, meropenem, and non-interpretable due to insufficient evidence (IE) for clindamycin and vancomycin |
History of surgery for squamous infiltrating carcinoma 2 months ago with no additional therapy | |||||||
Roh et al. [12], (2019) | 83/F | Bacteremia | T. bernardiae | Doxycycline (6 days), then meropenem + teicoplanin | Cured | - | Resistant to penicillin G and erythromycin and was susceptible to gentamicin and vancomycin |
Lawrence et al. [13], (2018) | 45/M | Bacteremia and septic thrombophlebitis | T. bernardiae | Susceptible to penicillin, co-amoxiclav, cefuroxime, cotrimoxazole, erythromycin, linezolid, ciprofloxacin, doxycycline, imipenem, amikacin | |||
Schneider et al. [14], (2015) | 45/M | Bacteremia and diabetic foot ulcer | T. bernardiae | IV piperacillin/tazobactam, ciprofloxacin and gentamicin, then amoxicillin for 14 days | Cured | Susceptible to penicillin, piperacillin/tazobactam, linezolid, moxifloxacin, and rifampin | |
Calatrava et al. [15], (2019) | 39/F | Breast abscess | T. bernardiae | Cloxacillin, then amoxicillin-clavulanic acid for 10 days | Cured | Susceptible to ciprofloxacin, gentamicin, imipenem, linezolid, penicillin, rifampicin, tetracycline, vancomycin, and resistant to trimethoprim-sulfamethoxazole, clindamycin, and erythromycin | |
Pan et al. [16], (2019) | 5/M | Brain abscess | T. bernardiae | Triple therapy of vancomycin, cefepime, and metronidazole for 6 weeks, then oral amoxicillin for 6 months | Cured | ||
Cobo et al. [17], (2017) | 69/F | Postop infection | T. bernardiae | Amoxicillin/clavulanate | Cured | History of rectal cancer and chemo in the past | Susceptible to penicillin G, linezolid, amoxicillin/clavulanate, and resistant to ciprofloxacin |
Rattes et al. [18], (2016) | 24/F | Postop infection | T. bernardiae | Piperacillin/tazobactam and vancomycin, then amoxicillin/clavulanate | Cured | Resistant to erythromycin and clindamycin and susceptible to levofloxacin, linezolid, vancomycin, and penicillin | |
Gowe et al. [4], (2018) | 57/M | Bone infection-septic arthritis | T. bernardiae | Doxycycline | Cured | Susceptible to penicillin, ceftriaxone, meropenem, vancomycin, and doxycycline | |
Adderson et al. [19], (1998) | 19/F | Bone infection-osteitis | T. bernardiae | Clindamycin for 6 weeks | Cured | 4-year history of steroids and cyclophosphamide for glomerulonephritis dt SLE | Susceptible to vancomycin, penicillin, clindamycin, and resistant to metronidazole |
Bemer et al. [20], (2009) | 63/M | Bone infection-olecranon bursitis | Arcanobacterium bernardiae | Clindamycin and fusidic acid for 3 weeks | Cured | Susceptible to aminoglycosides, erythromycin, clindamycin, pristinamycin, rifampin, cotrimoxazole, and vancomycin |
Statement of Ethics
Ethical approval is not required for this study in accordance with local or national guidelines. Written informed consent was obtained from the patient’s next of kin for publication of the details of their medical case and any accompanying images.
Conflict of Interest Statement
The authors have no conflicts of interest to declare.
Funding Sources
No funding required.
Author Contributions
Saliha Saleem was directly involved in literature review and wrote the main body of the manuscript and discussion. William Roland did the final review and editing of the case. Abdullah Lodhi assisted in literature review.
Data Availability Statement
All data generated or analyzed during this study are included in this article and its online supplementary material. Further enquiries can be directed to the corresponding author.